| 66.63 0.25 (0.38%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 82.41  |
1-year : | 87.88 |
| Resists | First : | 70.56 |
Second : | 75.23 |
| Pivot price | 65.3 |
|||
| Supports | First : | 62.99 | Second : | 52.41 |
| MAs | MA(5) : | 66.03  |
MA(20) : | 66.65 |
| MA(100) : | 65.93 |
MA(250) : | 72.53 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 44.4 |
D(3) : | 37.5 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 89.64 | Low : | 58.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GEHC ] has closed below upper band by 26.8%. Bollinger Bands are 33.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 67.09 - 67.34 | 67.34 - 67.54 |
| Low: | 65.09 - 65.41 | 65.41 - 65.66 |
| Close: | 66.16 - 66.64 | 66.64 - 67.03 |
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Fri, 25 Sep 2026
GEHC Looks 21.6% Undervalued on GF Value™ as Dividend Hike Highl - GuruFocus
Wed, 23 Sep 2026
GE HealthCare Technologies Inc. (GEHC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 23 Sep 2026
GE HealthCare (GEHC) is Down 28% and Wall Street is Starting to Buy. Is the Selloff Finally Over? - Insider Monkey
Wed, 23 Sep 2026
GE HealthCare (GEHC) is Down 28% and Wall Street is Starting to Buy. Is the Selloff Finally Over? - Yahoo Finance
Tue, 22 Sep 2026
GE HealthCare Appoints Pascal Desroches to Board Committees - TipRanks
Tue, 22 Sep 2026
AT&T CFO to join GE HealthCare (Nasdaq: GEHC) board in 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 452 (M) |
| Shares Float | 450 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 94.1 (%) |
| Shares Short | 17,430 (K) |
| Shares Short P.Month | 18,450 (K) |
| EPS | 4.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 24.29 |
| Profit Margin | 9.3 % |
| Operating Margin | 14.9 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 19.3 % |
| Qtrly Rev. Growth | 5.8 % |
| Gross Profit (p.s.) | 18.61 |
| Sales Per Share | 47.08 |
| EBITDA (p.s.) | 7.94 |
| Qtrly Earnings Growth | 16.7 % |
| Operating Cash Flow | 2,100 (M) |
| Levered Free Cash Flow | 1,570 (M) |
| PE Ratio | 15.35 |
| PEG Ratio | 1.7 |
| Price to Book value | 2.74 |
| Price to Sales | 1.41 |
| Price to Cash Flow | 14.33 |
| Dividend | 0.03 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|